8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 12, 2026·SEC
Adicet Bio, Inc.(ACET)Earnings, Financials & Key Ratios
ACET•NASDAQ
$8.60
Price updated Jul 7, 2026
AboutAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$116M+4.5%
- Net Income-$117M+0.3%
- EPS (Diluted)-16.95+20.3%
- ROE-67.55%-2.9%
ACET Price & Volume
Adicet Bio, Inc. (ACET) stock price & volume — 10-year historical chart
Loading chart...
ACET Growth Metrics
Adicet Bio, Inc. (ACET) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.37%
Return on Capital
10 Years-34.57%
5 Years-48.45%
3 Years-64.1%
Last Year-65.71%
ACET Recent Earnings
Adicet Bio, Inc. (ACET) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.88+35.8%
$2.93
Rev
—
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$2.94+9.0%
$3.23
Rev
—
$3M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$4.64-11.5%
$4.16
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$5.44-6.3%
$5.12
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.88vs $2.93+35.8% | — |
| Q2 2026 | Mar 12, 2026 | $2.94vs $3.23+9.0% | —vs $3M |
| Q4 2025 | Nov 5, 2025 | $4.64vs $4.16-11.5% | — |
| Q3 2025 | Aug 7, 2025 | $5.44vs $5.12-6.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Adicet Bio, Inc. (ACET)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.60 | $80.39M | -0.51 | — | — | -67.55% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $115.72 | $5.64B | -30.61 | — | — | -244.61% | — | |
| $1.07 | $139.01M | -1.07 | 266.65% | -1360.61% | -91.94% | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — |
Compare ACET vs Peers
Adicet Bio, Inc. (ACET) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACET SEC Filings & Documents
Adicet Bio, Inc. (ACET) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ACET posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACET Frequently Asked Questions
Adicet Bio, Inc. (ACET) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ACET profitable?
Adicet Bio, Inc. (ACET) reported a net loss of $108.8M for fiscal year 2025.
Dividend & Returns
What is ACET's return on equity?
Adicet Bio, Inc. (ACET) has a return on equity (ROE) of -67.6%. Negative ROE indicates the company is unprofitable.
What is Adicet Bio, Inc.'s free cash flow?
Adicet Bio, Inc. (ACET) had negative free cash flow of $91.6M in fiscal year 2025, likely due to heavy capital investments.